Algert Global LLC Biocryst Pharmaceuticals Inc Transaction History

Algert Global LLC

$3.72 Billion
Q3 2024

A detailed history of Algert Global LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Algert Global LLC holds 516,209 shares of BCRX stock, worth $3.92 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

516,209

Previous 353,133 46.18%

Holding current value

$3.92 Million

Previous $2.18 Million 79.79%

% of portfolio

0.11%

Previous 0.07%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$6.41 - $8.69 $1.05 Million - $1.42 Million	163,076 Added 46.18%	516,209 $3.92 Million
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $228,434 - $375,561	55,311 Added 18.57%	353,133 $2.18 Million
Q1 2024 May 14, 2024	SELL	$4.89 - $7.65 $190,431 - $297,913	-38,943 Reduced 11.56%	297,822 $1.51 Million
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $645,756 - $877,865	129,670 Added 62.61%	336,765 $2.02 Million
Q3 2023 Nov 13, 2023	SELL	$6.71 - $7.92 $566,733 - $668,931	-84,461 Reduced 28.97%	207,095 $1.47 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $212,767 - $269,321	30,570 Added 11.71%	291,556 $2.05 Million
Q1 2023 May 12, 2023	BUY	$7.94 - $11.84 $818,153 - $1.22 Million	103,042 Added 65.24%	260,986 $2.18 Million
Q4 2022 Feb 13, 2023	BUY	$10.5 - $14.2 $638,578 - $863,601	60,817 Added 62.62%	157,944 $1.81 Million
Q3 2022 Nov 15, 2022	BUY	$10.79 - $14.81 $206,509 - $283,448	19,139 Added 24.54%	97,127 $1.22 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $77,905 - $176,547	9,874 Added 14.5%	77,988 $825,000
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $555,550 - $949,626	48,058 Added 239.62%	68,114 $1.11 Million
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $284,995 - $353,988	20,056 New	20,056 $288,000

Others Institutions Holding BCRX

# of Institutions

279

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Biocryst Pharmaceuticals Inc Transaction History